Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154117 | 0.82 | LMNA (0.55) | CYP1A2LMNASMN1; SMN2CCKBRHTT | |
| SCHEMBL633304 | 0.82 | LMNA (0.55) | CYP1A2LMNASMN1; SMN2CCKBRHTT | |
| SCHEMBL633303 | 0.82 | LMNA (0.55) | CYP1A2LMNASMN1; SMN2CCKBRHTT | |
| SCHEMBL23286062 | 0.81 | GLA (0.50) | HTR2CALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL23295510 | 0.81 | IDO1 (0.52) | CYP1A2 | |
| SCHEMBL23295513 | 0.81 | IDO1 (0.52) | CYP1A2 | |
| SCHEMBL23295511 | 0.81 | IDO1 (0.52) | CYP1A2 | |
| SCHEMBL29205771 | 0.81 | ITGB3 (0.50) | CYP1A2 | |
| Hydrochloric Acid SCHEMBL29854262 | 0.80 | GLA (0.49) | HTR2CALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL25889273 | 0.79 | CYP1A2 (0.48) | CYP1A2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640488-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-05-05 | — | — | US | disclosed |
| US-10633366-B2 | Antibacterial compounds | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-04-28 | — | — | US | disclosed |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2020-03-26 | — | — | US | disclosed |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-08-22 | — | — | US | disclosed |
| US-20190161472-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-05-30 | — | — | US | disclosed |
| WO-2017211759-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017211760-A1 | NEW ANTIBACTERIAL COMPOUNDS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-14 | — | — | WO | disclosed |
| EP-2256114-B1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| EP-2256114-B1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7906510-B2 | Amide derivative and pharmaceutical composition containing the same | Dainippon Sumito Pharma Co., Ltd. (JP) | 2011-03-15 | — | — | US | disclosed |
| EP-2256114-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Sumitomo Pharma Co., Ltd. (JP) | 2010-09-30 | — | — | US | disclosed |
| WO-2009104729-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | 大日本住友製薬株式会社 (JP) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161472-A1 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, LAS1L, MRPL19 | CYP1A2 1035/4885CHEK1 4000/4885LMNA 1441/4885 |
| US-20200095225-A9 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | CYP1A2 4147/4885CHEK1 3886/4885LMNA 3976/4885 |
| US-10633366-B2 | Antibacterial compounds | MRPL21, LAS1L, MRPL19 | CYP1A2 584/4885CHEK1 3969/4885LMNA 1729/4885 |
| US-20190256495-A1 | NEW ANTIBACTERIAL COMPOUNDS | MRPL21, CLPP, NRDC | CYP1A2 4147/4885CHEK1 3886/4885LMNA 3976/4885 |
| US-10640488-B2 | Antibacterial compounds | MRPL21, CLPP, NRDC | CYP1A2 3385/4885CHEK1 3888/4885LMNA 3985/4885 |
| US-20100249399-A1 | AMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR4, MC2R, HTR1D | CYP1A2 1665/4885CHEK1 4582/4885LMNA 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.